Metabolism and anticancer activity of the curcumin analogue, dimethoxycurcumin

Clinical Cancer Research

Volumn 13, Issue 4, 2007, Pages 1269-1277

  Tamvakopoulos, Constantin ^a,d   Dimas, Konstantinos ^a   Sofianos, Zacharias D ^a   Hatziantoniou, Sophia ^a   Han, Zhiyong ^b   Liu, Zhong Li ^c   Wyche, James H ^b   Pantazis, Panayotis ^a,b  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c LANZHOU UNIVERSITY   (China)

^d BIOMEDICAL RESEARCH FOUNDATION   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CURCUMIN; DIMETHOXYCURCUMIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG POTENCY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL GROWTH PROCESSES; COLONIC NEOPLASMS; CURCUMIN; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG STABILITY; FEMALE; FLOW CYTOMETRY; HCT116 CELLS; HUMANS; MALE; MICE; MICROSOMES, LIVER;

EID: 33947281080     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1839     Document Type: Article

References (45)

1. Gafner S, Lee S-K, Guendet M, et al. Biologic evaluation of curcumin and structural derivatives in cancer chemoprevention model systems. Phytochemistry 2004;65:2849-59.
2. Shishodia S, Sethi G, Aggarwal BB. Curcumin: getting back to the roots. Ann N Y Acad Sci 2005;1056:206-17.
3. Sharma RA, Gescher AJ, Steward WP. Curcumin: the story so far. Eur J Cancer 2005;41:1955-68.
4. Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 2006;71:1397-421.
5. Maheshwari RK, Singh AK, Gaddipati J, Srimal RC. Multiple biological activities of curcumin: a short review. Life Sci 2006;78:2081-7.
6. Sarkat FH, Li Y. Cell signaling pathways altered by natural chemopreventive agents. Mutat Res 2004;555:53-64.
7. Campbell FC, Collett GP. Chemopreventive properties of curcumin. Future Oncol 2005;1:405-14.
8. Mukhopadhyay A, Bueso-Ramos C, Chatterjee D, Pantazis P, Aggarwal BB. Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene 2001;20:7597-609.
9. Martin-Cordero C, Lopez-Lazaro M, Galvez M, Ayuso MJ. Curcumin as a DNA topoisomerase II poison. J Enzyme Inhib Med Chem 2003;18:505-9.
10. Chaudhary LR, Hruska KA. Inhibition of cell survival signal protein kinase B/Akt by curcumin in human prostate cancer cells. J Cell Biochem 2003;89:1-5.
11. Collett GP, Campbell FC. Curcumin induces c-jun N-terminal kinase-dependent apoptosis in HCT116 human colon cancer cells. Carcinogenesis 2004;25:2183-9.
12. Chendil D, Ranga RS, Meigooni D, Sathishkumar S, Ahmed MM. Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3. Oncogene 2004;23:1599-607.
13. Fang J, Lu J, Holmgren A. Thioredoxin reductase is irreversibly modified by curcumin. A novel molecular mechanism for its anticancer activity. J Biol Chem 2005;280:25284-90.
14. Gao X, Deep D, Jiang H, Lin YB, Dulchavsky SA, Gautam SC. Curcumin differentially sensitizes malignant glioma cells to TRAIL/Apo2L-mediated apoptosis through activation of procaspases and release of cytochrome c from mitochondria. J Exp Ther Oncol 2005;5:39-48.
15. Lee KW, Kim JH, Lee HJ, Surh YJ. Curcumin inhibits phorbol ester-induced up-regulation of cycloxygenase-2 and matrix metalloproteinase-9 by blocking ERK1/2 phosphorylation and NF-κB transcriptional activity in MCF10A human breast epithelial cells. Antioxid Redox Signal 2005;7:1612-20.
16. Deeb DD, Jiang H, Gao X, Divine G, Dulchavsky SA, Gautam SC. Chemosensitization of hormone-refractory prostate cancer cells by curcumin to TRAIL-induced apoptosis. J Exp Ther Oncol 2005;5:81-91.
17. Yeh CH, Chen TP, Wu YC, Lin YM, Jing-Lin P. Inhibition of NFκB activation with curcumin attenuates plasma inflammatory cytokines surge and cardiomyocytic apoptosis following cardiac ischemia/reperfusion. J Surg Res 2005;125:109-16.
18. Adams BK, Cai J, Armstrong J, et al. EF24, a novel synthetic curcumin analogue, induces apoptosis in cancer cells via a redox-dependent mechanism. Anticancer Drugs 2005;16:263-75.
19. Lo Tempio MM, Veena MS, Steele HL, et al. Curcumin suppresses growth of head and neck squamous cell carcinoma. Clin Cancer Res 2005;11:6994-7002.
20. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003;23:363-98.
21. Furness MS, Robinson TP, Ehlers T, et al. Antiangiogenic agents: studies on fumagillin and curcumin analogs. Curr Pharm Des 2005;11:357-73.
22. Chakrabarty S, Ghosh U, Bhattacharya NP, Bhattacharya RK, Roy M. Inhibition of telomerase activity and induction of apoptosis by curcumin in K-562 cells. Mutat Res 2006;596:81-90.
23. Wang R, Zhang Y, Banerjee S, Li Y, Sarkar FH. Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells. Cancer 2006;106:2503-13.
24. Sung-ai C, Kumari AL, Khar A. Effect of curcumin on normal and tumor cells: role of glutathione and Bcl-2. Mol Cancer Ther 2004;3:1101-8.
25. Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001;21:2895-900.
26. 2 production. Cancer Res 2001;61:1058-64.
27. Sharma RA, McLelland HR, Hill KA, et al. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 2001;7:1894-900.
28. Ireson CR, Jones DJL, Orr S, et al. Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol Biomarkers Prev 2002;11:97-104.
29. Pan M-H, Huang T-M, Lin J-K. Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos 2000;27:486-94.
30. Asai A, Miyazawa T. Occurrence of orally administered curcuminoid as glucuronide and glucuronide/sulfate conjugates in rat plasma. Life Sci 2000;67:2785-93.
31. Chen W-F, Deng S-L, Zhou B, Yang L, Liu Z-L. Curcumin and its analogues as potent inhibitors of low density lipoprotein oxidation: H-atom abstraction from the phenolic groups and possible involvement of the 4-hydroxy-3- methoxyphenyl groups. Free Radic Biol Med 2006;40:526-35.
32. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer drug screening. J Natl Cancer Inst 1990;82:1107-14.
33. Pluquet O, North S, Bhoumik A, Dimas K, Ronai Z, Hainaut A. The cryoprotective aminothiol WR1065 activates p53 through a kinase. J Biol Chem 2003;278:11879-87.
34. Pantazis P, Kozielski AJ, Mendoza JT, Early JA, Hinz HR, Giovanella BC. Camptothecin derivatives induce regression of human ovarian carcinomas grown in nude mice and distinguish between non-tumorigenic and tumorigenic cells in vitro. Int J Cancer 1993;53:868-71.
35. Pantazis P, Early JA, Mendoza JT, DeJesus AR, Giovanella BC. Cytotoxic efficacy of 9-nitrocamptothecin in the treatment of human malignant melanoma cells in vitro. Cancer Res 1994;54:771-6.
36. Pantazis P, Chatterjee D, Han Z, Wyche JH. Differentiation of human malignant melanoma cells that escape apoptosis following treatment with 9-nitrocamptothecin in vitro. Neoplasia 2000;1:231-40.
37. Hu X, Balan KV, Ramos-DeSimone N, Wyche JH, Han Z, Pantazis P. Differential susceptibility to 9-nitrocamptothecin (9-NC)-induced apoptosis in clones derived from a human ovarian cancer cell line: possible implications in the treatment of ovarian cancer patients with 9-NC. Anticancer Drugs 2003;14:427-36.
38. Hollingshead M. Intraperitoneal and subcutaneous tumor models for assessing anti-neoplastic agents on rodents. In: Taylor GP, editor. Current protocols in pharmacology. New York: John Wiley & Sons; 2000. p. 5.28.6-5.20.14.
39. Mague JT, Alworth WL, Payton FL. Curcumin and derivatives. Acta Crystallogr C 2004;C60:608-10.
40. Liu A, Lou H, Zhao L, Fan P. Validated LC/MS/MS assay for curcumin and tetrahydrocurcumin in rat plasma and application to pharmacokinetic study of phospholipid complex of curcumin. J Pharm Biomed Anal 2006;40:720-7.
41. Jiang H, Timmermann B, Gang D. Use of liquid chromatography-electrospray ionization tandem mass spectrometry to identify diarylheptanoids in turmeric (Curcuma Ionga L.) rhizome. J Chromatogr A 2006;1111:21-31.
42. Chowdhury H, Walia S, Saxena V. Isolation, characterization, and insect growth inhibitory activity of major turmeric constituents and their derivatives against Schistocerca gregaria (Forsk) and Dysdercus koenigii (Walk). Pest Manag Sci 2000;56:1086-92.
43. Mauriala T, Chauret N, Oballa R, Nicoll-Griffith DA, Bateman KP. A strategy for identification of drug metabolites from dried blood spots using triple-quadrupole/linear ion trap hybrid mass spectrometry. Rapid Commun Mass Spectrom 2005;19:1984-92.
44. Hopfgartner G, Husser C, Zell M. Rapid screening and characterization of drug metabolites using a new quadrupole-linear ion trap mass spectrometer. Rapid Commun Mass Spectrom 2003;38:138-50.
45. Ohtsu H, Xiao Z, Ishida J, et al. Antitumor agents. 217. Curcumin analogues as novel androgen receptor antagonists with potential as anti-prostate cancer agents. J Med Chem 2002;45:5037-42.